title: [Diabetes and osteoporosis].
abstract: Diabetes alters bone mass and/or quality and increases fracture risk. However, in type 2 diabetes, bone mineral density (BMD) is usually not diminished, pertaining to increased weight and fat mass, which complicates the diagnosis of osteoporosis by DXA (T-score <-2.5). Similarly, estimates of fracture probability by FRAX may underestimate fracture risk in type 2 diabetes. Adequate glycemic control with insulin and/or oral antidiabetics decreases fracture risk, whereas thiazolidinediones increase it. Eventually, osteoporosis drugs such as bisphosphonates and SERMs seem to have similar efficacy in diabetic and non-diabetic patients.
authors.affiliation: Pr Serge Ferrari Service des maladies osseuses, Département des spécialités de medeciné interne HUG, 1211 Genève. serge.ferrari@unige.ch
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
mesh_terms: D015502:Absorptiometry, Photon; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D058866:Osteoporotic Fractures / Q000209:etiology* / Q000517:prevention & control; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D007004:Hypoglycemic Agents; D020845:Selective Estrogen Receptor Modulators